Skip to content

Welcome Debiopharm as a new corporate member

Date: October 3, 2023

The ACDM: Association for Clinical Data Management is delighted to welcome Debiopharm as a new corporate member.

Debiopharm is an independent biopharmaceutical company based in Switzerland with an ongoing commitment to improve patient outcomes and quality of life in oncology and bacterial infections. Their main activities include drug development, drug manufacturing and digital health investment.

Members gain many benefits from membership, including:

  • Access to training courses at a discounted rate
  • Assign full ACDM membership to all individuals within your organisation
  • Place an organisation profile, description and logo on the ACDM website
  • Advertise jobs for your positions within your organisation
  • Reduced price attendance at conferences and symposia
  • Free attendance at Hot Topics

Find out more about becoming a corporate member here.

 


 

Explore More News

Launch of Online Training from ACDM

The Association for Clinical Data Management is delighted to announce the launch of Online . . .

Read More

ACDM 2019 Awards Finalists

The Association for Clinical Data Management are delighted to announce the finalists for . . .

Read More

Castor EDC to Sponsor ACDM19

The Association for Clinical Data Management (ACDM) are delighted to announce that Castor . . .

Read More

Danone Nutricia Research to Sponsor ACDM19

The Association for Clinical Data Management (ACDM) are delighted to announce that . . .

Read More

ACDM19 Conference Programme

The Association for Clinical Data Management is delighted to announce the Full Programme . . .

Read More

Record Number of Abstracts Submitted for ACDM19

The deadline for Abstracts for ACDM19 passed on the 30th September and the Association for . . .

Read More

Phastar Sponsor ACDM19

The Association for Clinical Data Management are delighted to announce that PHASTAR are . . .

Read More

Launch of Annual ACDM Awards

The Association for Clinical Data Management are delighted to announce the introduction of . . .

Read More